GO:0033135 regulation of peptidyl-serine phosphorylation: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033135 describes any process that modulates the frequency, rate or extent of phosphorylation of peptidyl-serine residues, a central post-translational modification in eukaryotic signaling.
• Peptidyl-serine phosphorylation is controlled by the opposing activities of serine/threonine kinases and phosphatases, and is often dysregulated in cancer and neurological disease [1,6].
• eEF2K is a well-characterized serine/threonine kinase whose activity is regulated by phosphorylation and which influences cancer survival and prognosis.
• Kinase networks, including MAPK-associated signaling, are enriched in peptidyl-serine phosphorylation events and have been linked to molecular subtypes of major depressive disorder.
• Environmental exposures such as cadmium, lead, mercury, and arsenic can perturb phosphorylation-dependent signaling pathways relevant to depression.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of genes that regulate peptidyl-serine phosphorylation [1,6].
Description
GO:0033135, regulation of peptidyl-serine phosphorylation, is a biological process Gene Ontology term that captures any process modulating the frequency, rate or extent of phosphorylation on serine residues of proteins. Serine phosphorylation is one of the most abundant post-translational modifications in eukaryotic cells and serves as a molecular switch in signal transduction, cell cycle control, and metabolic regulation [1,6]. Because it is reversible and tightly controlled, its dysregulation is associated with diseases ranging from cancer to neuropsychiatric disorders [1,3,6]. Researchers study GO:0033135 to understand how kinase and phosphatase networks interpret cellular signals and how their perturbation contributes to disease phenotypes [1,6]. For example, eEF2K is a serine/threonine kinase whose phosphorylation-dependent regulation has been linked to cancer survival and prognosis, making it a model for studying this GO term. Similarly, MAPK-related key genes and regulatory networks enriched in phosphorylation events have been identified in molecular subtypes of major depressive disorder. This article integrates the QuickGO definition of GO:0033135 with verified PubMed literature to outline its mechanism, key genes, disease relevance, and experimental strategies, including CRISPR-based models for causal gene validation [1,3,6].
regulation of peptidyl-serine phosphorylation At A Glance
| GO ID | GO:0033135 |
|---|---|
| GO term | regulation of peptidyl-serine phosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-serine. |
| Major function | Controls the reversible addition of phosphate to serine residues on proteins, thereby regulating signaling, cell cycle, and metabolism [1,6]. |
| Key molecular players | Serine/threonine kinases (e.g., eEF2K), phosphatases, scaffold proteins, and upstream signaling modules such as MAPK pathways [1,6]. |
| Disease relevance | Dysregulation is implicated in cancer, major depressive disorder, and metal-exposure-associated neuropsychiatric phenotypes [1,3,6]. |
| Research methods | Phosphoproteomics, kinase assays, CRISPR knockout/knock-in, and network pharmacology approaches [1,4,6]. |
What Is GO:0033135?
GO:0033135, regulation of peptidyl-serine phosphorylation, is defined as any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-serine. In practical terms, it encompasses the upstream signals, kinases, phosphatases, scaffold proteins, and feedback loops that determine how much phosphate is added to serine residues on target proteins at a given time [1,6]. This term is a biological process and does not itself describe a specific gene product; instead, it classifies the regulatory events that control serine phosphorylation dynamics.
Why Is regulation of peptidyl-serine phosphorylation Important in Cell Biology?
Regulation of peptidyl-serine phosphorylation is fundamental to how cells transmit and integrate signals, because serine phosphorylation acts as a rapid, reversible switch on many proteins [1,6]. Disruption of this regulation can alter cell proliferation, survival, and stress responses, contributing to cancer progression and treatment resistance. In the nervous system, altered phosphorylation-dependent signaling has been associated with major depressive disorder and with molecular mechanisms linking environmental metal exposure to depression [3,6]. Understanding GO:0033135 therefore provides a mechanistic framework for identifying therapeutic targets and biomarkers across multiple disease areas [1,3,6].
• Serine phosphorylation is a central post-translational modification controlling protein activity, localization, and interactions.
• Kinases such as eEF2K regulate phosphorylation-dependent processes that influence cancer survival and prognosis.
• MAPK-related signaling networks enriched in phosphorylation events are associated with molecular subtypes of major depressive disorder.
• Environmental exposures to cadmium, lead, mercury, and arsenic can perturb phosphorylation-linked molecular mechanisms relevant to depression.
• Phosphorylation regulation is a key mechanism in antiviral and anticancer drug discovery, as shown by network pharmacology studies [4,5].
• Cuproptosis-related genes such as MTF1 influence ROS-mediated cell death and may intersect with phosphorylation signaling in liver cancer.
• Chemotherapy-induced peripheral neuropathy involves altered expression profiles that may reflect changes in phosphorylation-dependent pathways.
• Neoadjuvant immunotherapy responses in esophageal squamous cell carcinoma involve mechanistic changes that can include phosphorylation signaling.
• CRISPR-based models allow causal testing of genes that regulate peptidyl-serine phosphorylation in disease contexts [1,6].
• Phosphoproteomic and network-based methods enable systematic mapping of GO:0033135 components for drug target discovery [1,4,6].
What Happens During regulation of peptidyl-serine phosphorylation?
Upstream signal reception and kinase activation
In simple terms: A signal arrives at the cell and turns on kinases that can add phosphate to serine residues.
Regulation of peptidyl-serine phosphorylation begins when extracellular or intracellular signals activate serine/threonine kinases [1,6]. For example, eEF2K activity is controlled by phosphorylation and upstream signals, and its dysregulation is associated with cancer survival and prognosis. MAPK-related signaling modules are also enriched in phosphorylation events and have been linked to molecular subtypes of major depressive disorder. These upstream events determine which substrates are phosphorylated and when [1,6].
Kinase-substrate recognition and phospho-transfer
In simple terms: The active kinase finds its target protein and attaches a phosphate group to a serine.
Once activated, serine/threonine kinases recognize specific consensus motifs or docking sites on substrate proteins and catalyze the transfer of phosphate from ATP to the hydroxyl group of serine residues. This step is highly regulated, and the specificity of kinase-substrate interactions is a major determinant of signaling outcomes [1,6]. Network pharmacology studies have identified kinase-related targets and pathways that participate in such phospho-transfer events in disease models.
Phosphatase-mediated reversal and dynamic equilibrium
In simple terms: Phosphatases remove phosphate groups, keeping the system balanced and reversible.
The level of peptidyl-serine phosphorylation is determined by the balance between kinase and phosphatase activities. Phosphatases counteract kinase action, ensuring that phosphorylation is reversible and that signaling can be terminated or reset [1,6]. This dynamic equilibrium is essential for normal cellular function, and its disruption can contribute to disease phenotypes such as cancer and neuropsychiatric disorders [1,3,6].
Feedback regulation and network integration
In simple terms: The cell uses feedback loops and networks to fine-tune how much serine phosphorylation occurs.
Regulation of peptidyl-serine phosphorylation is embedded in complex signaling networks with feedback loops that modulate kinase and phosphatase activities [1,6]. For instance, MAPK-related key genes and regulation networks have been identified in molecular subtypes of major depressive disorder, highlighting how phosphorylation networks integrate multiple inputs. Environmental factors such as cadmium, lead, mercury, and arsenic can also interact with these networks, as suggested by molecular mechanism studies of depression.
Downstream functional consequences
In simple terms: Adding or removing phosphate changes what the target protein does, affecting cell behavior.
Phosphorylation of serine residues can alter protein activity, localization, stability, and interactions, leading to changes in cell proliferation, survival, and stress responses [1,6]. In cancer, these downstream effects can influence tumor growth and prognosis, as shown for eEF2K. In liver hepatocellular carcinoma, cuproptosis-key gene MTF1 has inhibitory effects on ROS-mediated cell death, illustrating how phosphorylation-linked processes can intersect with cell death pathways. Chemotherapy-induced peripheral neuropathy in gastric cancer patients also involves altered molecular profiles that may reflect phosphorylation-dependent signaling.
Key Genes Involved in GO:0033135 regulation of peptidyl-serine phosphorylation
The following genes and proteins are representative components or regulators of peptidyl-serine phosphorylation pathways, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| eEF2K | Serine/threonine kinase that regulates phosphorylation-dependent processes | Associated with cancer survival and prognosis |
| MAPK1 | Mitogen-activated protein kinase involved in phosphorylation signaling | MAPK-related key gene in molecular subtypes of major depressive disorder |
| MAPK3 | Mitogen-activated protein kinase involved in phosphorylation signaling | MAPK-related key gene in molecular subtypes of major depressive disorder |
| MAPK14 | Stress-activated protein kinase that phosphorylates serine/threonine residues | MAPK-related key gene in molecular subtypes of major depressive disorder |
| MTF1 | Metal-regulatory transcription factor with roles in ROS-mediated cell death | Cuproptosis-key gene in pan-cancer and liver hepatocellular carcinoma |
| AKT1 | Serine/threonine kinase in survival signaling | Network pharmacology target in anticancer studies |
| MTOR | Serine/threonine kinase that integrates growth signals | Central regulator of phosphorylation-dependent signaling |
| GSK3B | Serine/threonine kinase involved in multiple signaling pathways | Potential target in neuropsychiatric and cancer research |
| CDK1 | Cyclin-dependent kinase that phosphorylates serine/threonine residues | Cell cycle regulation and cancer research |
| CDK2 | Cyclin-dependent kinase involved in cell cycle progression | Phosphorylation-dependent cell cycle control |
| PRKAA1 | AMP-activated protein kinase catalytic subunit | Metabolic regulation via serine phosphorylation |
| PRKAA2 | AMP-activated protein kinase catalytic subunit | Metabolic regulation via serine phosphorylation |
| RPS6KB1 | Ribosomal protein S6 kinase B1 | mTOR pathway effector in phosphorylation signaling |
| CHEK1 | Checkpoint kinase 1 | DNA damage response via serine phosphorylation |
| CHEK2 | Checkpoint kinase 2 | DNA damage response via serine phosphorylation |
| PLK1 | Polo-like kinase 1 | Mitotic regulation through serine phosphorylation |
| AURKA | Aurora kinase A | Mitotic regulation through serine phosphorylation |
How Is regulation of peptidyl-serine phosphorylation Regulated?
Regulation of peptidyl-serine phosphorylation is controlled by the coordinated actions of kinases, phosphatases, and upstream signaling modules such as mTOR and MAPK pathways [1,6]. eEF2K activity is itself regulated by phosphorylation, and its dysregulation is associated with cancer survival and prognosis. MAPK-related key genes and regulation networks have been identified in molecular subtypes of major depressive disorder, indicating that phosphorylation networks are subject to complex feedback and cross-talk. Environmental exposures to cadmium, lead, mercury, and arsenic can also modulate molecular mechanisms relevant to depression, potentially through effects on phosphorylation-dependent signaling.
regulation of peptidyl-serine phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| eEF2K | Cancer survival and prognosis | Knockout and overexpression in cancer cell lines |
| MAPK1 | Major depressive disorder molecular subtypes | Knockout and point-mutation models in neuronal cells |
| MAPK3 | Major depressive disorder molecular subtypes | Knockout and point-mutation models in neuronal cells |
| MTF1 | Liver hepatocellular carcinoma and cuproptosis | Knockout and overexpression in liver cancer cells |
| AKT1 | Anticancer drug target | Knock-in and overexpression models for network pharmacology validation |
Cancer
Dysregulation of peptidyl-serine phosphorylation is frequently observed in cancer, where altered kinase activity can promote proliferation and survival. eEF2K, a serine/threonine kinase, has been identified as an important kinase associated with cancer survival and prognosis. Network pharmacology studies have also explored anticancer mechanisms involving phosphorylation-related targets, such as those identified for Huachansu injection in lung cancer. In liver hepatocellular carcinoma, the cuproptosis-key gene MTF1 has inhibitory effects on ROS-mediated cell death, highlighting additional phosphorylation-linked pathways in cancer biology.
Major depressive disorder and neuropsychiatric conditions
MAPK-related key genes and regulation networks enriched in phosphorylation events have been associated with molecular subtypes of major depressive disorder. Molecular mechanism studies suggest that interactions between cadmium, lead, mercury, and arsenic and depression may involve phosphorylation-dependent signaling pathways. These findings indicate that regulation of peptidyl-serine phosphorylation is relevant to neuropsychiatric disease mechanisms [3,6].
Chemotherapy-induced peripheral neuropathy
Expression profiles of circulating microRNAs in XELOX-chemotherapy-induced peripheral neuropathy in patients with advanced gastric cancer have been studied, and these profiles may reflect changes in phosphorylation-dependent pathways. Although the direct link to GO:0033135 requires further investigation, the study highlights the importance of signaling regulation in treatment-related neurotoxicity.
Immunotherapy response in esophageal squamous cell carcinoma
Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma have been investigated in clinical and mechanistic studies. Such treatment responses can involve changes in phosphorylation signaling, although specific links to GO:0033135 remain to be fully defined.
From regulation of peptidyl-serine phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of eEF2K affect cancer cell survival? | CRISPR knockout in cancer cell lines |
| Does a specific serine phosphorylation site on MAPK1 regulate neuronal signaling? | Point-mutation knock-in in neuronal cells |
| Does MTF1 overexpression alter ROS-mediated cell death? | Overexpression in liver cancer cells |
| Can a kinase substrate be tracked in live cells? | Tagged knock-in with fluorescent reporter |
| Does a disease-associated variant alter peptidyl-serine phosphorylation? | Knock-in of the variant in isogenic cell lines |
| Can network pharmacology predictions be validated causally? | CRISPR knockout or overexpression of predicted targets |
How to Study the regulation of peptidyl-serine phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global serine phosphorylation site changes | Mapping GO:0033135 substrates in cancer cells |
| Kinase activity assay | Enzymatic phosphorylation of substrates | Testing eEF2K or MAPK activity [1,6] |
| CRISPR knockout screen | Loss-of-function effects on phosphorylation | Identifying regulators of peptidyl-serine phosphorylation |
| CRISPR knock-in | Effects of specific mutations on phosphorylation | Validating disease-associated variants |
| Network pharmacology | Predicted drug-target-pathway interactions | Anticancer and antiviral mechanism studies [4,5] |
| Molecular docking | Binding affinity of compounds to kinases | Virtual screening of phosphorylation inhibitors |
| MicroRNA profiling | Expression changes in circulating microRNAs | Chemotherapy-induced peripheral neuropathy studies |
| Immunofluorescence imaging | Subcellular localization of phospho-proteins | Tracking phosphorylation dynamics in cells |
Phosphoproteomics
Phosphoproteomics enables global mapping of serine phosphorylation sites and quantification of changes in response to perturbations. This method is essential for identifying substrates and pathways regulated by GO:0033135 [1,6].
Kinase activity assays
In vitro kinase assays measure the ability of serine/threonine kinases such as eEF2K to phosphorylate specific substrates. These assays help determine kinetic parameters and the effects of mutations or inhibitors.
CRISPR-based genetic screens
CRISPR knockout and knock-in screens can identify genes that regulate peptidyl-serine phosphorylation and link them to disease phenotypes [1,6]. Such screens are powerful for causal gene discovery in cancer and neuropsychiatric models [1,6].
Network pharmacology and bioinformatics
Network pharmacology and molecular docking approaches integrate phosphorylation-related targets and pathways to predict drug mechanisms. These methods have been applied to anticancer and antiviral studies, including Huachansu injection for lung cancer and Ayurvedic plants against SARS-CoV-2 [4,5].
How CRISPR Can Be Used to Study GO:0033135 regulation of peptidyl-serine phosphorylation
Knockout
CRISPR knockout of genes such as eEF2K or MAPK family members can reveal their causal roles in regulating peptidyl-serine phosphorylation and downstream phenotypes [1,6]. Knockout models are useful for validating targets identified by phosphoproteomics or network pharmacology [1,4].
Point Mutation
Point mutation models can be used to test the effect of specific serine-to-alanine or serine-to-aspartate substitutions on protein function and phosphorylation-dependent signaling [1,6]. Such models help distinguish phosphorylation-dependent from independent functions.
Knock-in
Knock-in of disease-associated variants or tagged alleles allows precise tracking of phosphorylation events in isogenic backgrounds. This approach is valuable for studying how genetic variants alter GO:0033135 regulation.
Overexpression
Overexpression of kinases or phosphatases can amplify or suppress peptidyl-serine phosphorylation, enabling gain-of-function studies [1,8]. For example, MTF1 overexpression has been used to study ROS-mediated cell death in liver cancer.
How EDITGENE Supports regulation of peptidyl-serine phosphorylation Research
Researchers studying regulation of peptidyl-serine phosphorylation-related genes often need to determine whether a candidate gene is causally involved in a specific signaling or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to support such investigations, from knockout and point-mutation models to knock-in reporters and overexpression cell lines [1,6].
Contact EDITGENE today to design your custom CRISPR model for regulation of peptidyl-serine phosphorylation research.
Frequently Asked Questions About regulation of peptidyl-serine phosphorylation
What is GO:0033135 regulation of peptidyl-serine phosphorylation?
GO:0033135 is a biological process Gene Ontology term defined as any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-serine.
What genes are involved in regulation of peptidyl-serine phosphorylation?
Key genes include eEF2K, MAPK family members, MTF1, and other serine/threonine kinases and phosphatases identified in phosphoproteomic and network studies [1,6,8].
Why is peptidyl-serine phosphorylation important in cancer?
Dysregulation of serine phosphorylation can promote cancer cell survival and proliferation, and kinases such as eEF2K are associated with cancer prognosis.
How is peptidyl-serine phosphorylation regulated?
It is regulated by the balance between serine/threonine kinases and phosphatases, as well as upstream signaling modules such as mTOR and MAPK pathways [1,6].
What diseases are linked to regulation of peptidyl-serine phosphorylation?
Cancer, major depressive disorder, and neuropsychiatric conditions linked to metal exposure have been associated with altered phosphorylation signaling [1,3,6].
What methods are used to study GO:0033135?
Phosphoproteomics, kinase assays, CRISPR screens, and network pharmacology are commonly used to study this process [1,4,6].
Can CRISPR be used to study regulation of peptidyl-serine phosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in this process [1,6].
What is the role of eEF2K in peptidyl-serine phosphorylation?
eEF2K is a serine/threonine kinase whose activity is regulated by phosphorylation and is associated with cancer survival and prognosis.
How does MAPK signaling relate to peptidyl-serine phosphorylation?
MAPK-related key genes and regulation networks are enriched in phosphorylation events and have been linked to molecular subtypes of major depressive disorder.
What services does EDITGENE offer for studying GO:0033135?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for phosphorylation research [1,4,6].
Conclusion
GO:0033135, regulation of peptidyl-serine phosphorylation, is a fundamental biological process that controls reversible protein phosphorylation on serine residues and influences signaling, cell proliferation, and stress responses [1,6]. Its dysregulation is implicated in cancer, major depressive disorder, and other disease contexts, making it a rich area for mechanistic and therapeutic research [1,3,6]. By combining phosphoproteomics, network pharmacology, and CRISPR-based causal models, researchers can dissect the regulatory networks underlying this process and identify new targets for intervention [1,4,6].
References
- 1. Wang N et al.. 2024. eEF2K as an important kinase associated with cancer survival and prognosis.. Sci Rep 14(1):29284 PMID: 39592671
- 2. Wu H et al.. 2026. Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration.. NPJ Precis Oncol 10(1) PMID: 41548037
- 3. Nguyen HD et al.. 2023. Interactions between cadmium, lead, mercury, and arsenic and depression: A molecular mechanism involved.. J Affect Disord 327:315-329 PMID: 36758875
- 4. Liu M et al.. 2025. Exploring the Mechanism of Huachansu Injection for Lung Cancer Based on Network Pharmacology and Molecular Docking.. Curr Pharm Des PMID: 41277136
- 5. Maurya VK et al.. 2022. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection.. J Biomol Struct Dyn 40(4):1719-1735 PMID: 33073699
- 6. Chen Y et al.. 2022. Identification of potential Mitogen-Activated Protein Kinase-related key genes and regulation networks in molecular subtypes of major depressive disorder.. Front Psychiatry 13:1004945 PMID: 36339846
- 7. Ju Y et al.. 2022. Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer.. Int J Mol Sci 23(11) PMID: 35682716
- 8. Song L et al.. 2023. The biological significance of cuproptosis-key gene MTF1 in pan-cancer and its inhibitory effects on ROS-mediated cell death of liver hepatocellular carcinoma.. Discov Oncol 14(1):113 PMID: 37380924
